1. Noubiap JJ, Nansseu JR, Nyaga UF, et al. Worldwide trends in metabolic syndrome from 2000 to 2023: a systematic review and modelling analysis. Nat Commun. 2025;17(1):573. doi:10.1038/s41467-025-67268-5.
2. Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, Leong DP, et al. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023;389(14):1273-85. doi:10.1056/NEJMoa2206916.
3. Global Cardiovascular Risk Consortium; Magnussen C, Alegre-Diaz J, Al-Nasser LA, et al.; The Global Cardiovascular Risk Consortium. Global Effect of Cardiovascular Risk Factors on Lifetime Estimates. N Engl J Med. 2025;393(2):125-38. doi:10.1056/NEJMoa2415879.
4. Chen H, Liu L, Wang Y, Hong L, et al. Burden of cardiovascular disease attributable to metabolic risks in 204 countries and territories from 1990 to 2021. Eur Heart J Qual Care Clin Outcomes. 2025;11(4):467-76. doi:10.1093/ehjqcco/qcae090.
5. Ndumele CE, Rangaswami J, Chow SL, et al.; American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-35. doi:10.1161/CIR.0000000000001184.
6. Шляхто Е. В., Арутюнов Г. П., Бабенко А. Ю. и др. Согласительные междисциплинарные позиции наблюдательного комитета по метаболическому синдрому. Российский кардиологический журнал. 2026;31(10S):7130. doi:10.15829/1560-4071-2026-7130. EDN: GGKSWY.
7. Ostrominski JW, Arnold SV, Butler J, et al. Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999-2020. JAMA Cardiol. 2023;8:1050-60. doi:10.1001/jamacardio.2023.3241.
8. Vasan RS, Enserro DM, Beiser AS, Xanthakis V. Lifetime Risk of Heart Failure Among Participants in the Framingham Study. J Am Coll Cardiol. 2022;79(3):250-63. doi:10.1016/j.jacc.2021.10.043.
9. Lassen MCH, Ostrominski JW, Claggett BL, et al. Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study. Circulation. 2026;153(17):1268-80. doi:10.1161/CIRCULATIONAHA.125.077894.
10. Ostrominski JW, Claggett BL, Miao ZM, et al. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis. J Am Coll Cardiol. 2024;84(2):223-8. doi:10.1016/j.jacc.2024.05.005.
11. Pabon MA, Ostrominski JW, Wang X, et al. Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis. Eur Heart J. 2026: ehag162. doi:10.1093/eurheartj/ehag162.
12. Шляхто Е. В., Беленков Ю. Н., Бойцов С. А. и др. Частота, клиническая и прогностическая роль сахарного диабета 2 типа у пациентов c сердечной недостаточностью: субанализ исследования ПРИОРИТЕТ-ХСН. Российский кардиологический журнал. 2025;30(11S):6519. doi:10.15829/1560-4071-2025-6519.
13. Шляхто Е. В., Беленков Ю. Н., Бойцов С. А. и др. Резистентность и контроль артериальной гипертензии у пациентов с сердечной недостаточностью по данным исследования ПРИОРИТЕТ-ХСН. Российский кардиологический журнал. 2025;30(11S):6518. doi:10.15829/1560-4071-2025-6518.
14. Шляхто Е. В., Беленков Ю. Н., Бойцов С. А. и др. Оценка и клинико-прогностическая роль маркеров хронической болезни почек у амбулаторных пациентов с сердечной недостаточностью в реальной клинической практике: данные исследования ПРИОРИТЕТ-ХСН. Российский кардиологический журнал. 2025;30(11S):6521. doi:10.15829/1560-4071-2025-6521.
15. Bae JP, Kallenbach L, Nelson DR, et al. Obesity and metabolic syndrome in patients with heart failure with preserved ejection fraction: a cross-sectional analysis of the Veradigm Cardiology Registry. BMC Endocr Disord. 2024;24(1):59. doi:10.1186/s12902-024-01589-2.
16. Huang ZM, Chen WR, Su QW, Huang ZW. Prognostic Impact of Metabolic Syndrome in Patients With Heart Failure: A Meta-Analysis of Observational Studies. Front Cardiovasc Med. 2021;8:704446. doi:10.3389/fcvm.2021.704446.
17. Chronic Kidney Disease Prognosis Consortium; Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-81. doi:10.1016/S0140-6736(10)60674-5.
18. Ortiz A, Arreola Guerra JM, Chan JCN, et al.; Conference Participants. Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;108(4):555-71. doi:10.1016/j.kint.2025.04.005.
19. Ostrominski JW, Thierer J, Claggett BL, et al. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2023;11(11):1491-503. doi:10.1016/j.jchf.2023.05.015.
20. Tomasoni D, Vitale C, Guidetti F, et al. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2024;26(4):854-68. doi:10.1002/ejhf.3112.
21. Bayes-Genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023;25(11):1891-18. doi:10.1002/ejhf.3036.
22. Reddy YNV, Tada A, Obokata M, et al. Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting. Circulation. 2025;151(14):976-89. doi:10.1161/CIRCULATIONAHA.124.072156.
23. Parcha V, Patel N, Kalra R, et al. Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial. J Am Heart Assoc. 2021;10(7):e018689. doi:10.1161/JAHA.120.018689.
24. Savji N, Meijers WC, Bartz TM, et al. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. JACC Heart Fail. 2018;6(8):701-9. doi:10.1016/j.jchf.2018.05.018.
25. Gorica E, Geiger MA, Di Venanzio L, et al. Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment. Cardiovasc Diabetol. 2025;24(1):265. doi:10.1186/s12933-025-02774-w.
26. Hamo CE, Li X, Ndumele CE, et al. Association Between Cardiometabolic Comorbidity Burden and Outcomes in Heart Failure. J Am Heart Assoc. 2025;14(3):e036985. doi:10.1161/JAHA.124.036985.
27. Zhou Y, Fu L, Sun J, et al. Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF. Front Cardiovasc Med. 2021;8:698117. doi:10.3389/fcvm.2021.698117.
28. Cho Y, Park HS, Lee DH, et al. Novel metabolic syndrome subgroups and their association with cardiovascular outcomes: A data-driven cluster analysis of the UK Biobank. Diabetes Obes Metab. 2026;28(3):2286-96. doi:10.1111/dom.70424.
29. Lim AMW, Lim EU, Chen PL, Fann CSJ. Unsupervised clustering identified clinically relevant metabolic syndrome endotypes in UK and Taiwan Biobanks. iScience. 2024;27(7):109815. doi:10.1016/j.isci.2024.109815.